BioSpace News Archive

Syntekabio (KOSDAQ: 226330), an AI and NGS based drug development company, presented the result of STB-C017 animal experiments, a small molecule IDO/TDO dual inhibitor derived by Syntekabio’s AI drug discovery solution, at the 2020 American Association for Cancer Research (AACR) Annual Meeting, today at 00:00 EDT.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company’s pipeline of novel therapeutics in three presentations at the American Association for Cancer Research Virtual Annual Meeting II, taking place June 22-24, 2020 . The data to be presented will

In an effort to deliver outstanding solid-dose manufacturing and pharmaceutical equipment content, VertMarkets, Inc.'s Pharmaceutical Online and Techceuticals, LLC are pleased to announce the Virtual Pharma Expo to take place online Wednesday, May 20, 2020, with two, live sessions starting at 10:30AM and 1PM (eastern).

CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, congratulates Pfizer for announcing data from subjects that have completed the 12 month Phase Ib clinical trial presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. Today’s announcement included updates on the safety and efficacy data from muscle biopsies and the North

New data from the Pennsylvania Medical Society highlights some of the economic challenges that physician offices and other medical facilities have faced due to the drop in non-emergency care during the COVID-19 pandemic.

First published data with novel 1XX CAR signaling and programmed death-1 (PD-1) dominant negative receptor (DNR) checkpoint inhibition technologies

Digital technologies are emerging as a means for patients to access health information and healthcare services, particularly in recent months. New abstracts published this year in The Journal of Urology® highlight both the benefits and risks of using technology when managing health conditions

Urgent Response Network and Leading Distributor of Renovation Materials and Fixtures Working Together to Bring PPE Products to Americans during COVID-19

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced poster presentations related to AUTO5 in T cell lymphoma and AUTO6NG in small cell lung cancer, as well as an oral presentation related to AUTO7 in prostate cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on Jun 22 - 24, 2020.

Men of color in the United States are at an increased risk of prostate cancer and other prostate conditions, and despite advances in diagnosis and treatment, disparities still remain.